Psori Silk in Mild to Moderate Psoriasis: Randomized Phase I-II Study Volume 3 - Issue 3

Felix Pavlotsky*, Meir Babaev and Aviv Barzilai

Department of Dermatology, Sackler Faculty of Medicine, Sheba Medical Center, Tel-Hashomer, Israel

Received:July 17, 2021   Published:August 25, 2021

*Corresponding author:Department of Dermatology, Sackler Faculty of Medicine, Sheba Medical Center, Tel-Hashomer, Israel

DOI: 10.32474/OAJCAM.2021.03.000164

Abstract PDF

To view the Full Article   Peer-reviewed Article PDF

Abstract

Objectives: To assess efficacy and safety of Psori Silk in mild to moderate plaque psoriasis.

Material and Methods: Randomized double blind Psori Silk versus vehicle, 12 weeks treatment and 4 weeks follow up study. The primary endpoint was Modified PASI 50 at week 12, while the secondary endpoint included life quality assessment by DLQI.

Results: The Psori Silk group consisted of 23 patients with 34 lesions treated versus 22 and 36 in the vehicle group, respectively.

Modified PASI 50 seen in 59% versus 22.7% of patients in the active and the vehicle group, respectively (p< 0.001). Mean 33% DLQI improvement was observed in 65.2 versus 27.2% (p< 0.001) of active medicine and vehicle group patients, respectively. Mild and temporary discomfort at the application site was observed in 39 and 23% of the active medicine and vehicle group patients, respectively.

Conclusions: Psori Silk appear to be effective and safe treatment for mild to moderate plaque psoriasis. Keywords: plaque psoriasis; natural medicine; Psori Silk; Modified PASI 50; DLQI

Abstract| Introduction| Material and Methods| Results| Discussion| References |